Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas

Oligodendroglioma

Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma Correlation Between Psychological Stress and Progression of Newly Oligodendroglioma Towards Secondary Glioma Investigational Imaging Technique During Brain Surgery Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). PARP Inhibition for Gliomas (PI-4G or π4g) PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models Proteomic Characterization of Aggressive Oligodendrogliomas A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Sunitinib in Treating Patients With Recurrent Malignant Gliomas A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 Pediatric Long-Term Follow-up and Rollover Study Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Social Determinants of Health in Glioblastoma Population Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) Genetic Analysis of Brain Tumors Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Everolimus in Treating Patients With Recurrent Low-Grade Glioma Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma Everolimus With and Without Temozolomide in Adult Low Grade Glioma Clinical Development of MR Spectroscopy and Imaging in Brain Cancers Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants First in Patient Study for PF-06840003 in Malignant Gliomas A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas Prolonged Daily Temozolomide for Low-Grade Glioma Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Treatment Strategy for Low-grade Gliomas Neural Basis of Language Processing Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma Abemaciclib in Patients With Oligodendroglioma Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved